Form 4: Heron Therapeutics Executive Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, acquired stock options and restricted stock units on January 31, 2025.
Summary
- William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, acquired stock options and restricted stock units on January 31, 2025.
- He acquired 374,220 employee stock options with an exercise price of $1.70, vesting in 48 equal monthly installments starting one month after the grant date.
- Forbes also acquired 187,110 restricted stock units, vesting in 16 equal quarterly installments starting one quarter after the grant date.
- Following these transactions, Forbes directly owns 374,220 derivative securities (stock options) and 187,110 shares underlying the restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice, indicating confidence in the executive and aligning their interests with shareholders. There are no explicitly negative aspects mentioned.
Positives
- The acquisition of stock options and restricted stock units by a key executive suggests confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules for the stock options and restricted stock units suggest a multi-year commitment from the executive.
Industry Context
Stock option and RSU grants are common practice in the pharmaceutical industry to incentivize and retain key executives. The size of the grant is typical for an executive at Forbes' level.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and market capitalization.
- Companies like Amgen, Gilead Sciences, and Biogen commonly use stock options and restricted stock units to align executive interests with shareholder value.
- The vesting schedules (monthly for options, quarterly for RSUs) are also typical, designed to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the grant of stock options and restricted stock units positively, as it aligns executive interests with long-term company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of the transaction (grant of stock options and restricted stock units). |
| 01/31/2025 | Stock options vest in 48 equal monthly installments beginning one month after this date. |
| 01/31/2025 | Restricted stock units vest in 16 equal quarterly installments beginning one quarter after this date. |
| 01/31/2035 | Expiration date of the stock options. |
| 02/04/2025 | Date of the Form 4 filing. |
Keywords
Heron Therapeutics, HRTX, William P. Forbes, stock options, restricted stock units, EVP, Chief Development Officer, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.